Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Preliminary data shows Zimmer Biomet's autologous bone marrow aspirate extends amputation-free survival in patients with critical limb ischemia; shares up 2%

Published 11/15/2016, 11:11 AM
Updated 11/15/2016, 11:11 AM
Preliminary data shows Zimmer Biomet's autologous bone marrow aspirate extends amputation-free survival in patients with critical limb ischemia; shares up 2%
  • Zimmer Biomet Holdings (ZBH +2%) perks up on light volume in response to its announcement of positive interim results from a pivotal study, MOBILE, assessing its autologous concentrated bone marrow aspirate (cBMA) prepared with the MarrowStim PAD Kit for the treatment of critical limb ischemia (CLI).
  • The primary endpoint is amputation-free survival (AFS), time to major amputation and/or all-cause mortality at one year.
  • A preliminary analysis showed treatment with cBMA improved AFS compared to placebo with a comparable safety profile. A complete analysis of the data will support a U.S. marketing application.
  • CLI, the most severe form of peripheral artery disease, is caused by a profound obstruction of the arteries which significantly restricts blood flow to the extremities. Sufferers experience severe pain, skin ulcers, sores and eventually gangrene. Up to 30% do not qualify for traditional interventions to restore blood flow (revascularization) and are at high risk for amputation of the affected limb or death. CLI affects ~1.5M Americans.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.